Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 17-like protein 24

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q0WX57

UPID:

U17LO_HUMAN

Alternative names:

Deubiquitinating enzyme 17; Ubiquitin thioesterase 17; Ubiquitin-specific-processing protease 17

Alternative UPACC:

Q0WX57; A8MRA9; Q0WX56; Q3BEM1

Background:

Ubiquitin carboxyl-terminal hydrolase 17-like protein 24, also known as Deubiquitinating enzyme 17, Ubiquitin thioesterase 17, and Ubiquitin-specific-processing protease 17, plays a pivotal role in cellular processes. It functions as a deubiquitinating enzyme, meticulously removing conjugated ubiquitin from specific proteins. This action is crucial for regulating cell proliferation, cell cycle progression, apoptosis, cell migration, and the cellular response to viral infections.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase 17-like protein 24 could open doors to potential therapeutic strategies. Its involvement in key cellular processes underscores its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.